Premium
Androgens and prostate cancer risk: A prospective study
Author(s) -
Wirén Sara,
Stocks Tanja,
Rinaldi Sabina,
Hallmans Göran,
Bergh Anders,
Stenman UlfHåkan,
Kaaks Rudolf,
Stattin Pär
Publication year - 2007
Publication title -
the prostate
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.295
H-Index - 123
eISSN - 1097-0045
pISSN - 0270-4137
DOI - 10.1002/pros.20588
Subject(s) - prostate cancer , testosterone (patch) , medicine , prospective cohort study , prostate , sex hormone binding globulin , endocrinology , androgen , quartile , odds ratio , nested case control study , population , case control study , cancer , urology , oncology , gynecology , hormone , confidence interval , environmental health
BACKGROUND Androgens have been implicated in prostate tumorigenesis, but prospective studies have overall reported no association between circulating levels of androgens and risk of prostate cancer. However, some recent studies have shown that a high level of testosterone increase the risk of non‐aggressive tumors but is associated with a decreased risk of aggressive tumors. METHODS We prospectively measured plasma levels of total testosterone, androstanediol glucuronide (A‐diol‐g) and sex hormone binding globuline (SHBG) and calculated estimated levels of free testosterone, in a nested case‐control study of 392 cases and 392 matched controls. RESULTS None of the studied hormones were significantly associated with prostate cancer risk in the full study group or in subgroups according to tumor aggressiveness. Odds ratios in the full study group, for top versus bottom quartile, was for total testosterone 1.25 (95% CI = 0.79–2.00; P trend = 0.51); free testosterone, 1.31 (95% CI = 0.82–2.07; P trend = 0.35); A‐diol‐g, 0.88 (95% CI = 0.59–1.33; P trend = 0.77); and for SHBG, 1.01 (95% CI = 0.64–1.58; P trend = 0.94). Conclusions We found no significant associations between androgen levels and risk of prostate cancer in this population‐based, non‐screened cohort. Prostate 67: 1230–1237, 2007. © 2007 Wiley‐Liss, Inc.